Patent 10030005 was granted and assigned to Blueprint Medicines on July, 2018 by the United States Patent and Trademark Office.
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.